ABSTRACT
This chapter describes trade name, classification, approved indications for psychological disorders, available dosage forms, storage, and compatibility, usual dosage and administration, relative contraindications, and clinically significant drug interactions of mixed amphetamines. Decrements in predicted growth have been associated with long-term mixed amphetamines pharmacotherapy among children. Safety and efficacy of mixed amphetamines pharmacotherapy for women who are breast-feeding and their neonates and infants have not been established. Prescribe mixed amphetamines cautiously as adjunctive pharmacotherapy for the symptomatic management of A-D/HD and narcolepsy. Long-term amphetamine pharmacotherapy, or regular personal use, may lead to addiction and habituation. Abrupt discontinuation of high-dosage long-term amphetamine pharmacotherapy, or regular personal use, may result in the amphetamine withdrawal syndrome. Mixed amphetamines pharmacotherapy may decrease the neuronal uptake of guanethidine and, thus, decrease its antihypertensive action. Mixed amphetamines pharmacotherapy may alter the insulin requirements of patients who have insulin-dependent diabetes mellitus, particularly those patients who also have a restricted caloric diet.
